The effect of secukinumab treatment for psoriasis on serum cytokines and correlation with disease severity

Abstract

Objective: To investigate the effects of secukinumab treatment for psoriasis on different functional cytokines and inflammatory mediators in patients' serum Methods: Enzyme-linked immunosorbent assay was used to detect interleukin (IL)-1β and IL-1RA associated with intrinsic immunity; IL-6, IL-18, and growth regulated oncogene alpha (GROα) associated with neutrophils; IL-12, tumour necrosis factor (TNF)-α, and interferon (IFN)-γ associated with Th1; IL-23, IL-17A, and IL-22 associated with Th17; Thymus activation regulated chemokine (TARC), IL-13, and defensin beta 2 (DEFB2) associated with Th2; Vascular endothelial growth factor (VEGF)-A and IL-10 associated with angiogenesis; and IFN-γ associated with sepsis in the peripheral blood of 12 patients with common psoriasis treated with secukinumab and 15 healthy controls. IL-23, IL-17A, IL-22 associated with Th17; TARC, IL-13, DEFB2 associated with Th2; VEGF-A, IL-10 associated with angiogenesis and procalcitonin (PCT) associated with sepsis. The differences in expression of the above cytokines before and after treatment and the correlation with psoriasis disease severity[Psoriasis Area Severity Index(PASI) score], age, and disease duration were analyzed. Results:The mean PASI score of the enrolled patients with moderate to severe psoriasis was 21.6 ± 11.0 before treatment and decreased to below 1 after treatment. Serum IL-6; IL-18, GROα, IFN-γ, TNF-α, VEGF-A, and IL-17A were significantly higher than normal. And IL-17A and IFN-γ were positively correlated with disease duration and age, and IL-18 was positively correlated with PASI score. The expression levels of IL-6, GROα, VEGF-A, IFN-γ, TNF-α, IL-17A and IL-23 were significantly lower after secukinumab treatment compared with those before treatment, but the expression levels of IFN-γ, VEGF-A, TARC, IL-13, and DEFB2 were still significantly higher than those of normal subjects after treatment Conclusions: secukinumab clears skin lesions by antagonizing IL-17A and simultaneously decreasing the expression levels of IL-6, GRO α, VEGF-A, IFN-γ, TNF-α, IL-17A, and IL-23.

Sequential administration of paricalcitol followed by IL-17 blockade for progressive refractory IgA nephropathy patients

“…In light of our hypothesis, this could be potentially detrimental if IL-17 is blocked. Furthermore, in patients with ankylosing spondylitis, the use of SCK did not decrease Th2 cells 55 , paralleling recent findings in psoriatic patients 56 . In contrast, in our study we observed a significant decrease in Th2 cells.…”

The Role of Alarmins in the Pathogenesis of Rheumatoid Arthritis, Osteoarthritis, and Psoriasis

“…However, not all studies are coherent regarding secukinumab's effect on the level of this alarmin. A study by Wu et al showed higher serum levels of hBD2 after treatment with secukinumab than in a normal population [228]. Another study by Cardner et al analyzed the serum levels of beta-defensin in 2000 patients with psoriatic arthritis in a placebo-controlled phase-III clinical trial of secukinumab.…”